Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Antoon M. van Doornmalen"'
Autor:
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities
Externí odkaz:
https://doaj.org/article/8a2b28555c90401aa5082f21d4b9f7f8
Autor:
Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describ
Externí odkaz:
https://doaj.org/article/67d223be9e3a4daabf3fe18bdc0d30fd
Autor:
Guido J.R. Zaman, Rogier C. Buijsman, Jos de Man, Suzanne J.C. van Gerwen, Masaaki Sawa, Jeffrey Kooijman, Antoon M. van Doornmalen, Jelle Dylus, Judith R.F. de Vetter, Nicole Willemsen-Seegers, Martine B.W. Prinsen, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag
All IC50 values, reproducibility, other metrics, all correlations, ibrutinib biochemical IC50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83fe20e97c1e7c1a26b483c3f894380
https://doi.org/10.1158/1535-7163.22508719.v1
https://doi.org/10.1158/1535-7163.22508719.v1
Autor:
Guido J.R. Zaman, Rogier C. Buijsman, Jos de Man, Suzanne J.C. van Gerwen, Masaaki Sawa, Jeffrey Kooijman, Antoon M. van Doornmalen, Jelle Dylus, Judith R.F. de Vetter, Nicole Willemsen-Seegers, Martine B.W. Prinsen, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag
Additional reproducibility data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::003d19146fa08a6b23d7da87da7e39b2
https://doi.org/10.1158/1535-7163.22508731.v1
https://doi.org/10.1158/1535-7163.22508731.v1
Autor:
Rogier C. Buijsman, Guido J.R. Zaman, Wilhelmina E. van Riel, Joanne A. de Hullu, Anne M. van Altena, Antoon M. van Doornmalen, Jelle Dylus, Winfried R. Mulder, Judith E. den Ouden, Yvonne Grobben
Publikováno v:
Oncotarget
Background In epithelial ovarian cancer (EOC), 15-20% of the tumors do not respond to first-line chemotherapy (paclitaxel with platinum-based therapy), and in recurrences this number increases. Our aim is to determine the feasibility of cell prolifer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f5429fe2dd1e6e3fc041be629062ea2
https://doi.org/10.18632/oncotarget.27827
https://doi.org/10.18632/oncotarget.27827
Autor:
Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jill A P Spijkers-Hagelstein, Judith R F de Vetter, Jos de Man, Rogier C Buijsman, Guido J R Zaman
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125021 (2015)
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinat
Externí odkaz:
https://doaj.org/article/ef8b227b2f6d4dc1b37d97ccc9facfc1
Autor:
Anne M. van Altena, Leon F.A.G. Massuger, Winfried R. Mulder, Diep Vu-Pham, Joeri de Wit, Freek van Cauter, Yvonne Grobben, Judith E. den Ouden, Jos de Man, Antoon M. van Doornmalen, Joost C.M. Uitdehaag, Nicole Willemsen-Seegers, Jan Gerard Sterrenburg, Rogier C. Buijsman, Guido J.R. Zaman, Michelle Muller, Martine B.W. Prinsen
Publikováno v:
Frontiers in Immunology, 11
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2021)
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d73c71b4f0168a86defa0bee252d44e
https://pubmed.ncbi.nlm.nih.gov/33584686
https://pubmed.ncbi.nlm.nih.gov/33584686
Autor:
Jelle Dylus, Suzanne J.C. van Gerwen, Jeroen A.D.M. de Roos, Jeffrey J. Kooijman, Rogier C. Buijsman, Joost C.M. Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, Judith R.F. de Vetter, Guido J.R. Zaman, Masaaki Sawa, Antoon M. van Doornmalen, Martine B.W. Prinsen
Publikováno v:
Molecular Cancer Therapeutics. 15:3097-3109
Cancer cell line panels are important tools to characterize the in vitro activity of new investigational drugs. Here, we present the inhibition profiles of 122 anticancer agents in proliferation assays with 44 or 66 genetically characterized cancer c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ed14f398c8e1054a2189ad13aca4f6
https://doi.org/10.1158/1535-7163.mct-16-0403
https://doi.org/10.1158/1535-7163.mct-16-0403
Autor:
Jelle Dylus, Rogier C. Buijsman, Antoon M. van Doornmalen, Wilhelmina E. van Riel, Winfried R. Mulder, Anne van Altena, Guido J.R. Zaman, Diep Vu, Judith E. den Ouden
Publikováno v:
Cancer Research. 80:5604-5604
In epithelial ovarian cancer (EOC), 15-20% of tumors do not respond to first-line chemotherapy, consisting of platinum-based therapy plus paclitaxel, and in recurrences the response rate is even lower. PARP inhibitors synergize with platinum therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32c877090cb7373c44c756aa696b6442
https://doi.org/10.1158/1538-7445.am2020-5604
https://doi.org/10.1158/1538-7445.am2020-5604
Autor:
Rogier C. Buijsman, Diep Vu-Pham, Jos de Man, Joost C.M. Uitdehaag, Guido J.R. Zaman, Antoon M. van Doornmalen, Nicole Willemsen-Seegers, Yvonne Grobben
Publikováno v:
Molecular Cancer Therapeutics. 18:B060-B060
Introduction: Indoleamine 2,3-dioxygenase (IDO1) is a heme-containing oxidoreductase enzyme that converts L-tryptophan (Trp) into N’-formylkynurenine (NFK). IDO1 is broadly expressed by tumor cells as well as immune cells in the tumor microenvironm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1e71427ed0f8ce37ef141b4398a7705
https://doi.org/10.1158/1535-7163.targ-19-b060
https://doi.org/10.1158/1535-7163.targ-19-b060